Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.
Singh H, Asali S, Werner LL, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Neuberg DS, Fox EA, Stone RM, Attar EC. Singh H, et al. Among authors: fox ea. Leuk Res. 2011 Dec;35(12):1611-5. doi: 10.1016/j.leukres.2011.05.032. Epub 2011 Jun 21. Leuk Res. 2011. PMID: 21696826 Free PMC article.
Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.
Singh H, Werner LL, Asali S, DeAngelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Singh H, et al. Among authors: fox ea. Am J Hematol. 2011 Jul;86(7):625-7. doi: 10.1002/ajh.22041. Am J Hematol. 2011. PMID: 21681787 Free PMC article.
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ. Fischer T, et al. J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733134 Free PMC article. Clinical Trial.
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. Stone RM, et al. Ann Hematol. 2004;83 Suppl 1:S89-90. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124689 Clinical Trial. No abstract available.
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.
Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR. Jiang J, et al. Among authors: fox ea. Blood. 2004 Sep 15;104(6):1855-8. doi: 10.1182/blood-2004-02-0712. Epub 2004 Jun 3. Blood. 2004. PMID: 15178581 Free article.
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Stone RM, et al. Among authors: fox ea. Blood. 2005 Jan 1;105(1):54-60. doi: 10.1182/blood-2004-03-0891. Epub 2004 Sep 2. Blood. 2005. PMID: 15345597 Free article. Clinical Trial.
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Weisberg E, Roesel J, Bold G, Furet P, Jiang J, Cools J, Wright RD, Nelson E, Barrett R, Ray A, Moreno D, Hall-Meyers E, Stone R, Galinsky I, Fox E, Gilliland G, Daley JF, Lazo-Kallanian S, Kung AL, Griffin JD. Weisberg E, et al. Blood. 2008 Dec 15;112(13):5161-70. doi: 10.1182/blood-2008-02-138065. Epub 2008 Sep 26. Blood. 2008. PMID: 18820131 Free PMC article.
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD. Weisberg E, et al. Among authors: fox e. Mol Cancer Ther. 2010 Sep;9(9):2468-77. doi: 10.1158/1535-7163.MCT-10-0232. Epub 2010 Aug 31. Mol Cancer Ther. 2010. PMID: 20807780 Free PMC article.
NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.
Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD. Adamia S, et al. Among authors: fox ea. Blood. 2014 May 1;123(18):2816-25. doi: 10.1182/blood-2013-02-481507. Epub 2014 Feb 26. Blood. 2014. PMID: 24574459 Free PMC article.
135 results